Videos

WaveTec Vision Systems

By Tom Salemi | November 25, 2014

WaveTec Vision Systems ORA system is the first intra-operative diagnostic tool on the market to enhance visual outcomes in cataract surgery. It allows surgeons, in…

Read More

Alimera Sciences

By Tom Salemi | November 14, 2014

Alimera Sciences Inc. is ready to launch in the US its recently approved intravitreal implant, Iluvien, for treating diabetic macular edema. President and CEO Dan…

Read More

MC2 Biotek Group Offers Insights on PAD

By Tom Salemi | November 7, 2014

MC2 Biotek Group’s Co-Founder and President Jesper J. Lange updated attendees on the company’s PAD technology, which may make existing drugs easier to use. The…

Read More

Avalanche Biotechnologies Gives Ocular BioFactory Tour

By Tom Salemi | November 7, 2014

Thomas W. Chalberg, PhD presented an update on Avalanche Biotechnologies Inc.’s pipeline of products emerging from its integrated gene therapy discovery, development, and manufacturing platform,…

Read More

Allegro Gives Phase II News on Luminate

By Tom Salemi | November 7, 2014

[creativ_media type=”vimeo” url=”https://vimeo.com/110730931″] Vicken Karageozian, MD, Co-Founder and CTO of Allegro Opthalmics LLC, updated the OIS audience on the clinical trial progress of Luminate, a…

Read More

Ophthotech Shares Late-Stage Progress of Fovista

By Tom Salemi | November 7, 2014

CEO David R. Guyer, MD reports that Phase III clinical trials of Ophthotech Corp.’s Fovista, a first-in-class anti-PDGF agent for wet AMD combination therapy, are…

Read More

Monoclonal Antibody Company XOMA Corp. Shares New Strategy

By Tom Salemi | November 7, 2014

Monoclonal antibody company Xoma Corp. shared its new strategy of developing an internal pipeline of potential therapeutics. The company’s lead molecule is gevokizumab, a monoclonal…

Read More

Novaliq GmbH Using Semifluorinated Alkanes To Improve Solubility Of Topical Agents

By Tom Salemi | November 7, 2014

Novaliq GmbH is using semifluorinated alkanes to improve solubility of topical agents like cyclosporin and latanoprost on the ocular surface, according to CEO Bernhard Günther.…

Read More

Mobius Therapeutics Investigates Extending Mitosol Platform

By Tom Salemi | November 7, 2014

Ed Timm, President and CEO of Mobius Therapeutics LLC, provided an update on the investigations into extending the company’s Mitosol platform, presently used to administer…

Read More

GrayBug With Preclinical Work On Microparticle Anti-VEGF Compound GB-102

By Tom Salemi | November 7, 2014

GrayBug LLC is conducting preclinical work on its microparticle anti-VEGF compound GB-102, an extended-release injectable for wet AMD. The platform encapsulates the active drug ingredient…

Read More

Ocular Therapeutix

By Tom Salemi | November 7, 2014

Amarpreet Sawhney, PhD, President and CEO of Ocular Therapeutix shared his company’s vision: to transform the treatment of eye diseases with sustained release therapeutics. Ocular’s…

Read More

Allysta Pharmaceuticals Developing Multi-Kinase Inhibitor To Treat Glaucoma

By Tom Salemi | November 7, 2014

Aly1337 is a novel, small-molecule multi-kinase inhibitor that Allysta Pharmaceuticals Inc. is developing to treat glaucoma, said Henry Hsu, MD, Founder and CEO. Kinase, particularly…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.